Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Daniela Gilardi
Based on 13 articles published since 2010
(Why 13 articles?)
||||

Between 2010 and 2020, Daniela Gilardi wrote the following 13 articles about Crohn Disease.
 
+ Citations + Abstracts
1 Review Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 2019

Argollo, Marjorie / Fiorino, Gionata / Gilardi, Daniela / Furfaro, Federica / Roda, Giulia / Loy, Laura / Allocca, Mariangela / Peyrin-Biroulet, Laurent / Danese, Silvio. ·IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy. · Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. · Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, France. ·Curr Pharm Des · Pubmed #30864505.

ABSTRACT: INTRODUCTION: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Areas covered: In the next few years, also adalimumab biosimilars will become available for the treatment of inflammatory bowel disease (IBD). In fact, several of them (ABP501, BI 695501, GP2017, and SB5) have been approved by the European Medicines Agency (EMA) with the same indications of the reference product (Humira ®). Initial preclinical data proved a strong similarity between all biosimilars and the RP. Moreover, phase 3 studies in rheumatoid arthritis and psoriasis showed no differences in terms of efficacy, safety, and immunogenicity. Data on IBD patients are urgently needed. Expert opinion: Biosimilars of adalimumab showed equivalent clinical efficacy to the RP in other immunemediated diseases. However, defining the ideal patient's profile to receive or to be switched to a biosimilar, choosing one biosimilar vs. another, or cross-switching among biosimilars, will become the next challenge in IBD.

2 Review Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time? 2019

Argollo, Marjorie / Gilardi, Daniela / Roda, Giulia / Fiorino, Gionata / Peyrin-Biroulet, Laurent / Danese, Silvio. ·IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy. · Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. · Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, France. ·Curr Pharm Des · Pubmed #30848192.

ABSTRACT: Intestinal fibrosis, driven by chronic inflammation in Crohn's disease, can be defined as an excessive accumulation of extracellular matrix in the affected gut segment ultimately leading to an impaired wound healing and cumulative tissue damage, possibly resulting in organ dysfunction, formation of stenotic lesions and necessity of surgical intervention. Despite continuous advances in developing novel treatment modalities targeting different pathways to control chronic gut inflammation in CD, no effective anti-fibrotic agents have been released, to date. Thus, a better understanding of the molecular and cellular mechanisms underlying intestinal fibrosis is key to move this area of investigation forward.

3 Review Biosimilars of adalimumab: the upcoming challenge in IBD. 2019

Fiorino, Gionata / Gilardi, Daniela / Correale, Carmen / Furfaro, Federica / Roda, Giulia / Loy, Laura / Argollo, Marjorie / Allocca, Mariangela / Peyrin-Biroulet, Laurent / Danese, Silvio. ·IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Institute , Milan , Italy. · Department of Biomedical Sciences, Humanitas University , Milan , Italy. · Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University , Vandoeuvre-lès-Nancy , France. ·Expert Opin Biol Ther · Pubmed #30601098.

ABSTRACT:

4 Review Can IL-23 be a good target for ulcerative colitis? 2018

Allocca, Mariangela / Furfaro, Federica / Fiorino, Gionata / Gilardi, Daniela / D'Alessio, Silvia / Danese, Silvio. ·IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. Electronic address: mariangela.allocca@humanitas.it. · IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy. · IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. · Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. ·Best Pract Res Clin Gastroenterol · Pubmed #30060945.

ABSTRACT: A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis. Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD). This review aims to discuss the available data on IL-23 and Th17 cell pathways in UC, in order to define the role of IL-23 as possible target for the treatment of UC.

5 Review PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. 2018

Allocca, Mariangela / Gilardi, Daniela / Fiorino, Gionata / Furfaro, Federica / Argollo, Marjorie / Peyrin-Biroulet, Laurent / Danese, Silvio. ·a IBD Centre, Humanitas Clinical and Research Centre , Milan , Italy. · b Gastroenterology and Inserm U954, University Hospital of Nancy , Nancy , France. · c Department of Biomedical Sciences , Humanitas University , Milan , Italy. ·Expert Opin Investig Drugs · Pubmed #29985060.

ABSTRACT: INTRODUCTION: Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blocking its binding with the α4β7 integrin on leukocytes. This review discusses the available data on effectiveness and safety of PF-00547659 in IBD. Expert opinion: A phase II study in moderate-to-severe ulcerative colitis (UC) patients, both naïve and previously exposed to anti-tumor necrosis factors, showed that PF-00547659 was superior to placebo for induction of remission, response, and mucosal healing at week 12. In contrast, preliminary results in a similar study in Crohn's disease (CD) did not show a superiority of PF-00547659, suggesting that PF-00547659 may have limited impact over CD outcomes. However, the time frame needed to evaluate clinical effectiveness of PF-00547659 may be longer in CD patients, given its transmural characteristic. In addition, it should be taken into consideration the possibility of incorporating new tools and more objective parameters in disease assessment that are proven to better correlate with inflammation. Future randomized-controlled trials are needed to confirm the efficacy of PF-00547659 in CD.

6 Review IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. 2017

Furfaro, Federica / Gilardi, Daniela / Allocca, Mariangela / Cicerone, Clelia / Correale, Carmen / Fiorino, Gionata / Danese, Silvio. ·a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy. · b Department of Internal Medicine and Medical Specialties , Sapienza University , Rome , Italy. · c Department of Biomedical Sciences , Humanitas University , Rozzano , Milan , Italy. ·Expert Rev Clin Immunol · Pubmed #28067059.

ABSTRACT: INTRODUCTION: Adaptive immunity in intestinal inflammation may play a key role in the pathogenesis of Crohn's disease. In particular, interleukin (IL)-23 may be a key mediator in chronic intestinal inflammation by inducing the differentiation of naïve CD4 + T cells into Th17, with the production of several pro-inflammatory cytokines. Furthermore, IL-23 induces interferon-γ (IFN- γ) production from activated T cells, a critical cytokine in innate and adaptive immunity against infections. Areas covered: We aim to review the available data from literature regarding the role of IL-23, with a more specific focus on the recent progresses in the therapeutic modulation of this cytokine. Expert commentary: Increased knowledge regarding the role of IL-23 has allowed for the development of effective therapeutic progresses by blocking the IL-23 mediated pathways. Primary or secondary loss of response to anti-TNF therapies in Crohn's disease patients during the first year is widely described in literature: the development of new drugs, with alternative mechanisms of action, is thus a key point to consider for the optimal management of these subjects. Drugs blocking the IL-12/23 pathway showed a good efficacy and safety profile in immune-mediated diseases Further studies are necessary regarding the role of the single blockade of IL-23.

7 Review Emerging therapeutic targets and strategies in Crohn's disease. 2016

Furfaro, Federica / Fiorino, Gionata / Allocca, Mariangela / Gilardi, Daniela / Danese, Silvio. ·a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy. · b Department of Gastroenterology , University Study of Milan , Milan , Italy. ·Expert Rev Gastroenterol Hepatol · Pubmed #26766496.

ABSTRACT: Crohn's disease (CD) is an immune-mediated inflammatory bowel disease, in which inflammation is driven by a complex interaction between the microbiota, immune cells, genes and mediators. New mechanisms of action and several cytokines have been identified as factors involved in the inflammatory process in CD, and many new molecules have been developed to treat this complex disease. New agents have been developed that target leukocyte trafficking, block or adhesion molecules for example, as well as the development of antibodies against classic inflammatory cytokines or therapies directed against IL-12/23 and Janus kinases. The development of selective mechanisms of action and targeting of different cytokines or inflammatory mediators for each patient presents the biggest challenge for the future in CD therapy. Such agents are currently at different phases of development. We aim to review the current literature data on a targeted approach in CD, which could be promising alternative approach for CD patients in the near future.

8 Review Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 2014

Gilardi, Daniela / Fiorino, Gionata / Genua, Marco / Allocca, Mariangela / Danese, Silvio. ·IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy. ·Expert Rev Gastroenterol Hepatol · Pubmed #24813226.

ABSTRACT: The use of complementary and alternative medicine is wide-spread not only in Eastern countries, but also in the Western world. Despite the increasing evidence on the harmful effects induced by several naturopathic/homeopathic products, patients seem to appreciate these remedies, in particular because they consider them to be absolutely safe. This same phenomenon is common among inflammatory bowel disease (IBD) patients. As a result there is a significant request for scientific data to evaluate both the efficacy and safety of these remedies, and to support the use of such medications as adjuvant treatments to biological and synthetic drugs. We aimed to review the current evidence on efficacy and safety of some natural products that are believed to be effective in inflammatory bowel disease. Further perspectives for the clinical use of herbal products and strategies for improving knowledge about herbal products in IBD are also discussed.

9 Article Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation (ECCO) position paper. 2020

Fiorino, Gionata / Lytras, Theodore / Younge, Lisa / Fidalgo, Catarina / Coenen, Sofie / Chaparro, Maria / Allocca, Mariangela / Arnott, Ian / Bossuyt, Peter / Burisch, Johan / Campmans-Kuijpers, Marjo / de Ridder, Lissy / Dignass, Axel / Drohan, Ciara / Feakins, Roger / Gilardi, Daniela / Grosek, Jan / Groß, Evelyn / Hart, Ailsa / Jäghult, Susanna / Katsanos, Konstantinos / Lönnfors, Sanna / Panis, Yves / Perovic, Marko / Pierik, Marieke / Rimola, Jordi / Tulchinsky, Hagit / Gisbert, Javier P. ·Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. · IBD Center, Dept. of Gastroenterology, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy. · Hellenic Centre for Disease Control and Prevention, Athens, Greece. · Barts Health - Royal London Hospital, London, United Kingdom. · Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal. · Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. · Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. · Gastrointestinal Unit, Western General Hospital, Edinburgh, United Kingdom. · Imelda GI Clinical Research Centre, Imeldaziekenhuis Bonheiden, Bonheiden, Belgium. · Gastrounit, Medical Division, Hvidovre University Hospital, Hvidovre, Denmark. · University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands. · Erasmus Medical Center Children's Hospital Department of Paediatric Gastroenterology, Rotterdam, Netherlands. · Department of Medicine I , Agaplesion Markus Hospital, Goethe-University , Frankfurt am Main , Germany. · European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA), Brussels, Belgium. · Department of Cellular Pathology, Royal London Hospital, London, United Kingdom. · Department of Abdominal Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia. · IBD Unit , St. Mark's Hospital, Harrow, United Kingdom. · Stockholm Gastro Center, Karolinska Institutet Danderyds sjukhus, Stockholm, Sweden. · Department of Gastroenterology and Hepatology, Division of Internal Medicine, University and Medical School of Ioannina, Ioannina, Greece. · APHP Beaujon Department of Colorectal Surgery, Clichy, France. · Maastricht University Medical Center (MUMC) Department of NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands. · IBD unit, Radiology Department, Hospital Clínic of Barcelona, Barcelona, Spain. · Tel Aviv Sourasky Medical Center Department of Surgery, Tel Aviv, Israel. ·J Crohns Colitis · Pubmed #32032423.

ABSTRACT: The management of inflammatory bowel disease (IBD) is complex, and requires tight control of disease activity, close monitoring to avoid treatment side effects, healthcare professionals with expertise in IBD and an interdisciplinary, holistic approach. Despite various efforts to standardise structures, processes and outcomes1-8, and due to the high variability at the local, national and international levels, there are still no clear definitions or outcome measures available to establish quality of care standards for IBD patients that are applicable in all contexts and all countries. For this reason, the European Crohn's and Colitis Organisation (ECCO) supported the construction of a list of criteria summarising current standards of care in IBD. The list comprises 111 quality standard points grouped into three main domains (structure n=31, process n=42, outcomes n=38) and is based on scientific evidence, interdisciplinary expert consensus and patient-oriented perspectives. The list of proposed criteria is intended to represent the position of ECCO regarding the optimum quality of care that should be available to patients. Since healthcare systems and regulations vary considerably between countries, this list may require adaptation at local and national levels. It is recognised that not all these criteria that have been identified as optimal will be available in every unit. However, ECCO will continue its efforts to develop and coordinate projects and initiatives that will help to guarantee optimal quality of care for all IBD patients.

10 Article Is there a role for therapeutic sphingolipids in inflammatory bowel disease? 2020

Parigi, Tommaso Lorenzo / Roda, Giulia / Argollo, Marjorie / Gilardi, Daniela / Danese, Silvio. ·Department of Biomedical Sciences, Humanitas University, Milan, Italy. · IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy. · Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil. ·Expert Rev Gastroenterol Hepatol · Pubmed #31874053.

ABSTRACT:

11 Article Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. 2019

Argollo, Marjorie / Kotze, Paulo Gustavo / Lamonaca, Laura / Gilardi, Daniela / Furfaro, Federica / Yamamoto, Takayuki / Danese, Silvio. ·Department of Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil. · IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Institute, Milan, Italy. · IBD outpatient clinics, Catholic University of Parana (PUCPR), Curitiba, Brazil. · Department of Surgery and IBD Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Japan. · Department of Biomedical Sciences, Humanitas University, Milan, Italy. ·Curr Drug Targets · Pubmed #30894106.

ABSTRACT: Crohn's disease (CD) is an immune-mediated condition characterized by the transmural inflammation of the gut tissue, associated with progressive bowel damage often leading to surgical intervention. As operative resection of the damaged segment is not curative, a majority of patients undergoing intestinal resections for complicated CD present disease recurrence within 3 years after the intervention. Postoperative recurrence can be defined as endoscopic, clinical, radiological or surgical. Endoscopic recurrence rates within 1 year exceed 60% and the severity, according to the Rutgeerts' score, is associated with worse prognosis and can predict clinical recurrence (in up to 1/3 of the patients). Most importantly, about 50% of patients will undergo a reoperation after 10 years of their first intestinal resection. Therefore, the prevention of postoperative recurrence in CD remains a challenge in clinical practice and should be properly managed. We aim to summarize the most recent data on the definition, risk factors, assessment and treatment of postoperative CD recurrence.

12 Article Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. 2019

Vegni, Elena / Gilardi, Daniela / Bonovas, Stefanos / Corrò, Bianca E / Menichetti, Julia / Leone, Daniela / Mariangela, Allocca / Furfaro, Federica / Danese, Silvio / Fiorino, Gionata. ·Department of Clinical Psychology, University of Milan, Milan, Italy. · IBD Center, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy. · Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. ·J Crohns Colitis · Pubmed #30517669.

ABSTRACT: BACKGROUND: Inflammatory bowel diseases [IBD] are characterised by significant quality of life [QoL] impairment, as well as illness perception. Assessing illness perception may help in optimising the management of IBD patients. METHODS: In this single-centre, observational, transversal study, consecutive adult IBD patients were enrolled and stratified according to disease activity [active/remission]. The Revised Illness Perception Questionnaire [IPQ-R], based on identity, opinions, and causes of their disease was administered to all patients. Comparison within IPQ-R parameters was done between clinically active patients and those in remission. RESULTS: A total of 201 patients were enrolled (Crohn's disease [CD] = 47%). The most frequently reported IBD-related symptoms were fatigue [86.9%], loss of strength [83.3%], pain [80%], and weight loss [68.2%]. Active patients reported significantly more frequently fatigue [p = 0.005], sore eyes [p = 0.046], and sleep difficulties [p = 0.001], and reported more symptoms than controls [p = 0.023]. Overall, the patients considered stress [84.1%], altered immunity [69.32%], family problems [49.4%], and emotional status [40.9%] as the main causes of IBD. Work overload was more frequently considered as a disease cause in active patients than in those in remission [p = 0.002]. Smoking, family history, and previous inadequate therapies were considered as a relevant risk factor for illness by only 20% of patients. Active IBD patients had more negative thoughts on prognosis [p = 0.001] and more negative emotions [p < 0.0001]. Patients in remission were significantly more convinced about treatment control [p = 0.007] and had clearer understanding of illness [p = 0.009]. CONCLUSIONS: Illness perception is impaired in IBD patients. Adequate educational and psychological support may be helpful in the optimal management of IBD patients.

13 Article Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. 2018

Allocca, Mariangela / Fiorino, Gionata / Bonifacio, Cristiana / Furfaro, Federica / Gilardi, Daniela / Argollo, Marjorie / Peyrin-Biroulet, Laurent / Danese, Silvio. ·IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy. · Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. · Radiology, IRCCS Humanitas, Rozzano, Milano, Italy. · Department of Gastroenterology, Universidade Federal de São Paulo - UNIFESP, São Paulo, Brazil. · Department of Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Nancy, France. ·J Crohns Colitis · Pubmed #29982361.

ABSTRACT: Background: The comparative accuracy of bowel ultrasound [US] versus magnetic resonance enterography [MRE] in combination with colonoscopy [CS] in assessing Crohn's disease [CD] and influencing the decision-making process is unknown. Methods: Consecutive ileo-colonic CD patients seen in a tertiary referral centre were prospectively assessed by MRE, CS, and bowel US, within 1 week. Sensitivity, specificity, accuracy, positive predictive value [PPV], and negative predictive value [NPV] of bowel US in assessing localisation, enhancement [presence of vascularisation at Power Doppler], active disease [presence of ulcers at colonoscopy], strictures, fistulas, and abscesses were calculated using CS + MRE findings together as a reference standard. Two blinded inflammatory bowel disease [IBD] specialists reviewed MRE and bowel US findings and were asked to decide the therapeutic strategy [continue versus change therapy]. Kappa agreement with clinical decision was calculated. Results: Sixty CD patients [36 with endoscopic disease activity, 28 with complications] were enrolled. For localisation, sensitivity, specificity, accuracy, PPV, and NPV of bowel US were 88%, 96%, 91%, 96%, and 85%, respectively; for enhancement, 87%, 92%, 89%, 93%, and 86%; for activity, 92%, 100%, 96%, 100%, and 94%; for strictures, 75%, 86%, 81%, 78%, and 83%; for fistulas, 100%, 98%, 98%, 66%, and 100%; for abscesses, 100%, 96%, 96%, 33%, and 100%. The concordance of management of CD patients based on bowel US or MRE findings, alone, compared with clinical decision, was 0.768 and 0.767, respectively [p <0.001]. The concordance between bowel US and MRE on management of CD patients was 0.800 [p <0.001]. Conclusions: Bowel US is very accurate in assessing CD and is a non-invasive, easy-to-use tool to manage CD patients in clinical practice.